Biotech Values

[mcbio]

It is a real large deal, especially compared to LLY's JAK1/2 RA deal with INCY two years ago. I guess biotech deal price is going up.

I assume the hefty premium is due in large part to the fact that the drug is entirely differentiated from the competition (JAK1-specific) and the hope that this will translate into a benefit. Quite a deal for Galapagos.